Sareum Holdings PLC
RYH0
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
5
Stocks News & Analysis
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
stocks
Chart of the Week: Why ASX tech is poised for a comeback
The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,381.40 | 9.10 | -0.10% |
| CAC 40 | 8,676.38 | 1.44 | 0.02% |
| DAX 40 | 26,412.67 | 81.60 | 0.31% |
| Dow JONES (US) | 53,770.27 | 21.58 | -0.04% |
| FTSE 100 | 10,798.39 | 34.76 | -0.32% |
| HKSE | 25,396.51 | 43.66 | -0.17% |
| NASDAQ | 26,588.49 | 143.04 | 0.54% |
| Nikkei 225 | 68,308.59 | 784.53 | 1.16% |
| NZX 50 Index | 13,825.30 | 87.64 | 0.64% |
| S&P 500 | 7,748.50 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,188.50 | 4.40 | -0.05% |
| SSE Composite Index | 3,926.96 | 19.71 | -0.50% |